share_log

Biodexa Pharmaceuticals | 6-K/A: Report of foreign private issuer [Rules 13a-16 and 15d-16] (Amendment)

Biodexa Pharmaceuticals | 6-K/A: Report of foreign private issuer [Rules 13a-16 and 15d-16] (Amendment)

Biodexa Pharmaceuticals | 6-K/A：外國發行人報告(修正)
美股SEC公告 ·  07/19 13:06

Moomoo AI 已提取核心訊息

Biodexa Pharmaceuticals PLC has filed an amendment to its Form 6-K report with the U.S. Securities and Exchange Commission (SEC) on July 19, 2024. The amendment, referred to as Amendment No. 1, corrects previously disclosed information regarding the expected gross proceeds from a registered direct offering and the terms of the lock-up period on subsequent equity sales. The company now expects to receive approximately $5.0 million in gross proceeds before deducting fees and other expenses. Additionally, the lock-up period will end either 90 days after the closing of the offerings or the day after the company's ADSs' closing price exceeds US$2.00, whichever comes first. This amendment does not change any other information in the original Form 6-K report or reflect events post the original filing. The amended report will be incorporated by reference into the company's registration statements on Form S-8 and Form F-3.
Biodexa Pharmaceuticals PLC has filed an amendment to its Form 6-K report with the U.S. Securities and Exchange Commission (SEC) on July 19, 2024. The amendment, referred to as Amendment No. 1, corrects previously disclosed information regarding the expected gross proceeds from a registered direct offering and the terms of the lock-up period on subsequent equity sales. The company now expects to receive approximately $5.0 million in gross proceeds before deducting fees and other expenses. Additionally, the lock-up period will end either 90 days after the closing of the offerings or the day after the company's ADSs' closing price exceeds US$2.00, whichever comes first. This amendment does not change any other information in the original Form 6-K report or reflect events post the original filing. The amended report will be incorporated by reference into the company's registration statements on Form S-8 and Form F-3.
Biodexa Pharmaceuticals PLC於2024年7月19日向美國證券交易委員會（SEC）提交了Form 6-k報告的修正案。該修正案稱爲修正案1，糾正了有關注冊直接發售的預期總收益和後續股票銷售的鎖定期條款的先前披露信息。該公司現在預計在扣除費用和其他支出之前將獲得大約$500萬的總收益。此外，鎖定期將在發售結束後90天或公司ADS的收盤價超過2.00美元的次日結束，以先到者爲準。該修正案不改變原始Form 6-k報告中的任何其他信息，也不反映原始申報日後的事件。修改後的報告將被引用合併到公司的S-8和F-3形式的註冊聲明中。
Biodexa Pharmaceuticals PLC於2024年7月19日向美國證券交易委員會（SEC）提交了Form 6-k報告的修正案。該修正案稱爲修正案1，糾正了有關注冊直接發售的預期總收益和後續股票銷售的鎖定期條款的先前披露信息。該公司現在預計在扣除費用和其他支出之前將獲得大約$500萬的總收益。此外，鎖定期將在發售結束後90天或公司ADS的收盤價超過2.00美元的次日結束，以先到者爲準。該修正案不改變原始Form 6-k報告中的任何其他信息，也不反映原始申報日後的事件。修改後的報告將被引用合併到公司的S-8和F-3形式的註冊聲明中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間